One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Widening the tightrope: new abstract guidelines for BJD authors
A.M. Drucker,J.R. Ingram
doi : 10.1111/bjd.20498
Volume 185, Issue 4 p. 687-688
Commentary on the British Association of Dermatologists guidelines for the management of people with rosacea 2021
J. S. S. Ho,Y. Asai
doi : 10.1111/bjd.20631
Volume 185, Issue 4 p. 689-690
GUIDEMAP: an open-access dermatology guidelines repository
T.E. Sivesind,R.P. Dellavalle
doi : 10.1111/bjd.20652
Volume 185, Issue 4 p. 690-691
Bruton tyrosine kinase inhibition warrants further study for pemphigus
A.M. Drucker,N.H. Shear
doi : 10.1111/bjd.20623
Volume 185, Issue 4 p. 691-692
Pemphigus vulgaris (PV) is a rare and devastating autoimmune bullous disease. Until recently, treatment required high-dose oral corticosteroids and nontargeted immunomodulating agents such as intravenous immunoglobulin (IVIG), azathioprine, mycophenolate and cyclophosphamide. Rituximab, an anti-CD20 monoclonal antibody that works by depleting B cells, revolutionized treatment of PV. Rituximab can induce long-lasting remission off corticosteroids in 40% of patients, compared with 10% for mycophenolate.1 Rituximab has been a breakthrough, improving outcomes and decreasing IVIG utilization. However, there is still a need for safe and effective treatments to optimize outcomes for patients with PV. In this issue of the BJD, Murrell et al. present early-phase findings for a Bruton tyrosine kinase (BTK) inhibitor, rilzabrutinib, for the treatment of PV.2
Strengthening melanoma prevention and early detection among people with type 2 diabetes
A.E. Cust
doi : 10.1111/bjd.20633
Volume 185, Issue 4 p. 692-693
Prognosis after a diagnosis of cutaneous melanoma is strongly related to stage at diagnosis.1 As most countries rely on opportunistic skin checks rather than an organized screening programme for the early detection of melanoma, it is important to identify population characteristics that are associated with more aggressive melanomas, as these population subgroups could be targeted for heightened prevention and early detection strategies.
Growing evidence for an association between inflammatory skin disease and chronic kidney disease
J. Wan,K. Abuabara
doi : 10.1111/bjd.20632
Volume 185, Issue 4 p. 693-694
Diseases such as psoriasis, atopic dermatitis, hidradenitis suppurativa, alopecia areata, vitiligo, bullous pemphigoid and rosacea have different aetiologies, but are sometimes studied together as ‘chronic inflammatory skin diseases’ or ‘immune-mediated inflammatory skin diseases’. A growing body of literature has led to recognition that these conditions are frequently associated with other diseases that extend beyond the skin. While most comorbidity research on inflammatory skin diseases has focused on links to cardiovascular disease, cancer, infections and mental health conditions, a growing body of literature examines links to kidney disease.
Addressing the causality of the association of atopic dermatitis with depression and anxiety using Mendelian randomization
M. Standl
doi : 10.1111/bjd.20622
Volume 185, Issue 4 p. 694-695
An association of atopic dermatitis with depression and anxiety has been observed in several epidemiological studies, such as that by Schonmann et al.1 However, the underlying mechanisms, and whether this association is causal, is not yet clear. The study by Baurecht et al.2 in the current issue of the BJD is the first to investigate this important and frequently reported association using Mendelian randomization. This approach allows the causality of the observed effect to be studied, controlling for reverse causation, confounding and biases such as reporting or recall bias.3
Getting to the core of peripheral vascular malformations: measuring what matters
J. Tan
doi : 10.1111/bjd.20635
Volume 185, Issue 4 p. 695-696
The management of peripheral vascular malformations – previously limited to sclerotherapy, laser treatments and surgical excision – is progressing into the realm of molecular targeted therapies. Thus, it is timely that in this issue of the BJD, development of a patient-reported outcome measure addressing symptoms and appearance in vascular malformations (OVAMA questionnaire) is presented.1
Therapeutic biomarkers in hidradenitis suppurativa: one step closer to the clinic
J.W. Frew
doi : 10.1111/bjd.20513
Volume 185, Issue 4 p. 696-697
Hidradenitis suppurativa (HS) is a challenging disease to manage. Achieving long-term disease remission with medical monotherapy is often elusive. Selection of therapy is often based on personal experience and ‘trial and error’, and restricted by the limited number of options available. Evidence-based and pathogenesis-directed individualized therapies (primarily in the form of identification of predictive biomarkers) are tantalizing solutions to the uncertainty surrounding whether an individual patient will adequately respond to a specific medical therapy.
Decoding the pharmacogenetics of nonsteroidal anti-inflammatory drug hypersensitivity
C. Flores
doi : 10.1111/bjd.20693
Volume 185, Issue 4 p. 697-698
Hypersensitivity reactions triggered by nonsteroidal and anti-inflammatory drugs (NSAIDs) commonly develop with respiratory and/or cutaneous manifestation. Those typically displaying as skin reactions are commonly referred to as NSAID-induced acute urticaria/angioedema (NIUA). Familial aggregation of NSAID hypersensitivity is well known.1 Thus, although simple inheritance models of the condition are not expected, the evidence supports the influence of genetic factors in the development of this phenotype.
Data-driven prediction of biologic treatment responses in psoriasis: steps towards precision medicine
L. S. van der Schoot,J. M. P. A. van den Reek
doi : 10.1111/bjd.20625
Volume 185, Issue 4 p. 698-699
In this issue of the BJD, Geifman et al. defined subgroups or ‘trajectories’ of patients with psoriasis with similar patterns of disease severity (Psoriasis Area and Severity Index, PASI). The patients were studied over time using a data-driven latent class mixed-modelling approach.1 This modelling approach can be used to divide a heterogeneous population into a few homogeneous groups or ‘trajectories’. As such, patient characteristics in specific trajectories can be used to predict health outcomes such as treatment success.2, 3 With the increase in (expensive) treatment options for psoriasis, but still a substantial number of nonresponders per biologic, these analyses are very welcome. In this study, data of patients who were treated with various biologics were included. Four PASI trajectories were identified, with differences in clinical characteristics such as body mass index, baseline PASI, psoriasis subtype and the specific biologics.
Not all melanomas are created equal: a review and call for more research into nodular melanoma
C. Dessinioti,A.C. Geller,D.C. Whiteman,C. Garbe,J.J. Grob,J.W. Kelly,R.A. Scolyer,R.V. Rawson,A. Lallas,G. Pellacani,A.J. Stratigos
doi : 10.1111/bjd.20388
Volume 185, Issue 4 p. 700-710
Clinical experience and psychometric properties of the Cardiff Acne Disability Index (CADI)*
Y.T. Abdelrazik,F.M. Ali,M.S. Salek,A.Y. Finlay
doi : 10.1111/bjd.20391
Volume 185, Issue 4 p. 711-724
British Association of Dermatologists guidelines for the management of people with rosacea 2021*
P.J. Hampton,J. Berth-Jones,C.E. Duarte Williamson,R. Hay,T.A. Leslie,I. Porter,S. Rauz,D. Seukeran,R.T. Winn,M. Hashme,L.S. Exton,M.F. Mohd Mustapa,L. Manounah,on behalf of the British Association of Dermatologists’ Clinical Standards Unit
doi : 10.1111/bjd.20485
Volume 185, Issue 4 p. 725-735
Global Guidelines in Dermatology Mapping Project (GUIDEMAP): a scoping review of dermatology clinical practice guidelines*
W.Y. Haw,A. Al-Janabi,B.W.M. Arents,L. Asfour,L.S. Exton,D. Grindlay,S.S. Khan,L. Manounah,H. Yen,C.-C. Chi,E.J. van Zuuren,C. Flohr,Z.Z.N. Yiu
doi : 10.1111/bjd.20428
Volume 185, Issue 4 p. 736-744
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study*
D.F. Murrell,A. Patsatsi,P. Stavropoulos,S. Baum,T. Zeeli,J.S. Kern,A.-V. Roussaki-Schulze,R. Sinclair,I.D. Bassukas,D. Thomas,A. Neale,P. Arora,F. Caux,V.P. Werth,S.G. Gourlay,P. Joly,on behalf of the BELIEVE trial investigators
doi : 10.1111/bjd.20431
Volume 185, Issue 4 p. 745-755
Relationship between type 2 diabetes mellitus and markers of cutaneous melanoma aggressiveness: an observational multicentric study in 443 patients with melanoma*
E. Nagore,M.A. Martinez-Garcia,J.D. Gomez-Olivas,E. Manrique-Silva,A. Martorell,J. Bañuls,C. Carrera,P. Ortiz,J. Gardeazabal,A. Boada,E. de Eusebio,E. Chiner,C. Gonzalez,A. Pérez-Gil,D. Cullen,M. Formigón,B. de Unamuno,C. Navarro-Soriano,A. Muriel,D. Gozal
doi : 10.1111/bjd.19813
Volume 185, Issue 4 p. 756-763
The cardiovascular safety of oral alitretinoin: a population-based cohort study involving 19 513 patients exposed to oral alitretinoin*
F. Poizeau,F. Balusson,A.P. Jonville-Béra,E. Nowak,M.D. Drici,P.Y. Scarabin,C. Droitcourt,A. Dupuy,E. Oger
doi : 10.1111/bjd.20069
Volume 185, Issue 4 p. 764-771
Inflammatory skin diseases and the risk of chronic kidney disease: population-based case–control and cohort analyses*
Y. Schonmann,K.E. Mansfield,A. Mulick,A. Roberts,L. Smeeth,S.M. Langan,D. Nitsch
doi : 10.1111/bjd.20067
Volume 185, Issue 4 p. 772-780
Relationship between atopic dermatitis, depression and anxiety: a two-sample Mendelian randomization study
H. Baurecht,C. Welker,S.-E. Baumeister,S. Weidnger,C. Meisinger,M.F. Leitzmann,H. Emmert
doi : 10.1111/bjd.20092
Volume 185, Issue 4 p. 781-786
Development of a shared decision-making tool in vitiligo: an international study*
J. Shourick,M. Ahmed,J. Seneschal,T. Passeron,N. Andreux,A. Qureshi,E.Y. Chow,P.A. Natella,J. Harris,V.-T. Tran,K. Ezzedine
doi : 10.1111/bjd.20137
Volume 185, Issue 4 p. 787-796
Development of a condition-specific patient-reported outcome measure for measuring symptoms and appearance in vascular malformations: the OVAMA questionnaire
M.M. Lokhorst,S.E.R. Horbach,D.A. Young-Afat,M.L.E. Stor,L. Haverman,P.I. Spuls,C.M.A.M. van der Horst,the OVAMA Steering Group
doi : 10.1111/bjd.20429
Volume 185, Issue 4 p. 797-803
Potential predictive biomarkers of adalimumab response in patients with hidradenitis suppurativa*
Y. Cao,F. Hong,D.M. Conlon,L. Sidur,K.M. Smith,Y. Fang,C.A. Cuff,Z. Kaymakcalan,M.C. Ruzek
doi : 10.1111/bjd.20097
Volume 185, Issue 4 p. 804-814
Polymorphisms in eicosanoid-related biosynthesis enzymes associated with acute urticaria/angioedema induced by nonsteroidal anti-inflammatory drug hypersensitivity
R. Jurado-Escobar,I. Doña,J.R. Perkins,J.J. Laguna,R. Muñoz-Cano,A. García-Sánchez,P. Ayuso,M.J. Torres,C. Mayorga,J.A. Cornejo-García
doi : 10.1111/bjd.20440
Volume 185, Issue 4 p. 815-824
Defining trajectories of response in patients with psoriasis treated with biologic therapies
N. Geifman,N. Azadbakht,J. Zeng,T. Wilkinson,N. Dand,I. Buchan,D. Stocken,P. Di Meglio,R.B. Warren,J.N. Barker,N.J. Reynolds,M.R. Barnes,C.H. Smith,C.E.M. Griffiths,N. Peek,the BADBIR Study Group, on behalf of the PSORT Consortium
doi : 10.1111/bjd.20140
Volume 185, Issue 4 p. 825-835
Mohs micrographic surgery for patients living with HIV
A. Alani,N. Kibbi,T. Oliphant
doi : 10.1111/bjd.20417
Volume 185, Issue 4 p. 836-837
Forewarned is forearmed: chronic spontaneous urticaria as a potential risk to effective SARS-CoV-2 vaccine uptake and global public health
W.H. Bermingham,M.R. Ardern-Jones,A.P. Huissoon,M.T. Krishna
doi : 10.1111/bjd.20495
Volume 185, Issue 4 p. 838-839
Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study
A.S. Van Voorhees,L. Stein Gold,M. Lebwohl,B. Strober,H. Sofen,K. Papp,J. Bagel,Z. Zhang,M. Paris,Y. Wang
doi : 10.1111/bjd.20083
Volume 185, Issue 4 p. 840-842
Methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization predicts MRSA infection in inpatient paediatric cellulitis
R. Rrapi,S. Chand,S. Song,C.K Gabel,R. Shah,C. El Saleeby,D. Kroshinsky
doi : 10.1111/bjd.20439
Volume 185, Issue 4 p. 842-844
Skin cancers in lockdown: no impact on pathological tumour staging
N. Gaunt,R.L. Green,L.F. Motta,L.A. Jamieson
doi : 10.1111/bjd.20438
Volume 185, Issue 4 p. 844-846
YouTube as a source of educational information for natural hair
S. Shukla,A. Amuzie,D. Moslehi,E. Linos,J. Lester
doi : 10.1111/bjd.20402
Volume 185, Issue 4 p. 846-847
Alopecia barbae severity score: a novel scoring system to estimate the extent of beard loss and success of treatment
A.J. Stefanis,P. Arenberger,M. Arenbergerova,S. Gkalpakiotis
doi : 10.1111/bjd.20489
Volume 185, Issue 4 p. 847-849
Comparative performance of predictors of death from thin (? 1·0 mm) melanoma
M. Claeson,P. Baade,M. Marchetti,S. Brown,H.P. Soyer,B.M. Smithers,A.C. Green,D.C. Whiteman,K. Khosrotehrani
doi : 10.1111/bjd.20480
Volume 185, Issue 4 p. 849-851
Topical imiquimod as neoadjuvant therapy before Mohs micrographic surgery for basal cell carcinoma in the head and neck region: findings from a large retrospective study
C. Queirós,L. Silva,A. Miroux Catarino,J. Labareda,G. Catorze,I. Viana
doi : 10.1111/bjd.20487
Volume 185, Issue 4 p. 851-853
Skin checks and skin cancer diagnosis in Australian general practice before and during the COVID-19 pandemic, 2011–2020
J. Roseleur,D.A. Gonzalez-Chica,J. Emery,N.P. Stocks
doi : 10.1111/bjd.20494
Volume 185, Issue 4 p. 853-855
Novel evidence of androgen receptor immunoreactivity in skin tunnels of hidradenitis suppurativa: assessment of sex and individual variability
W. Yu,J. Barrett,P. Liu,A. Parameswaran,E.S. Chiu,C.P. Lu
doi : 10.1111/bjd.20520
Volume 185, Issue 4 p. 855-858
Relapse of chilblain-like lesions during the second wave of the COVID-19 pandemic: a cohort follow-up
T. Hubiche,F. Le Duff,E. Fontas,J. Rapp,C. Chiaverini,T. Passeron
doi : 10.1111/bjd.20584
Volume 185, Issue 4 p. 858-859
Kawasaki-like multisystem inflammatory syndrome associated with COVID-19 in an adult: a case report
R. Dabas,G. Varadaraj,S. Sandhu,A. Bhatnagar,R. Pal
doi : 10.1111/bjd.20574
Volume 185, Issue 4 p. 859-861
Multifocal extracardiac rhabdomyomas: extending the phenotype of Birt–Hogg–Dubé syndrome
D. S. Bajwa,S. Cook,R. Winn,I. M. Winship,A. McQueen,A. Husain,N. Rajan
doi : 10.1111/bjd.20521
Volume 185, Issue 4 p. 861-863
Adalimumab dose intensification in hidradenitis suppurativa: effectiveness and safety results of a multicentre study
E.M. Sánchez Martínez,G. Murray,F. Alfageme Roldán,R. García Ruiz,A.M. Tobin,C.C. Zouboulis
doi : 10.1111/bjd.20525
Volume 185, Issue 4 p. 863-865
Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab
P.M. Brunner,C. Conrad,R. Vender,S. Grond,C. Schuster,H. Patel,W. Xu,J.M. Carrascosa Carrillo
doi : 10.1111/bjd.20527
Volume 185, Issue 4 p. 865-867
Ivermectin in the management of a scabies outbreak in a long-term care facility
S.L. Walker,M.G. Head,J. Middleton,J.A. Cassell
doi : 10.1111/bjd.20484
Volume 185, Issue 4 p. 868-868
Response to ‘A call to standardize the BCC:SCC ratio’
B.C. Ma,V.N. Sahni,L.D. Edwards,D.R. Sahni,A.M. Secrest
doi : 10.1111/bjd.20486
Volume 185, Issue 4 p. 868-869
Response to ‘A call to standardize the BCC:SCC ratio’: reply from the authors
Z. Jiyad,L. Marquart,A.C. Green
doi : 10.1111/bjd.20490
Volume 185, Issue 4 p. 869-870
Subcutaneous rituximab for autoimmune bullous diseases
C. Riquelme-Mc Loughlin,P. Iranzo
doi : 10.1111/bjd.20493
Volume 185, Issue 4 p. 870-871
Response to ‘Decline in the use of phototherapy in France from 2010 to 2019’
E. Eadie,M. Gallacher,A. Gorczynski,L. Smith,R.S. Dawe,Photonet, the Managed Clinical Network for Ultraviolet Phototherapy in Scotland
doi : 10.1111/bjd.20586
Volume 185, Issue 4 p. 871-872
Response to ‘COVID-19-associated multisystem inflammatory syndrome in adults with Kawasaki disease-like cutaneous manifestations’
Y.S. Pathania
doi : 10.1111/bjd.20590
Volume 185, Issue 4 p. 872-872
Response to ‘COVID-19-associated multisystem inflammatory syndrome in adults with Kawasaki disease-like cutaneous manifestations’: reply from the authors
T.P. Afra,M.M. Siraj,M. Razmi T
doi : 10.1111/bjd.20638
Volume 185, Issue 4 p. 872-873
Isolated cutaneous larva migrans over the scalp in a hod carrier
A. Sil,A. Panigrahi,J.D. Pramanik
doi : 10.1111/bjd.20589
Volume 185, Issue 4 p. e157-e157
Diabetes mellitus and melanoma aggressiveness
doi : 10.1111/bjd.20668
Volume 185, Issue 4 p. e159-e159
Some studies have suggested a relationship between type 2 diabetes mellitus and an increased incidence of a skin cancer called melanoma, at least in men. Tumour aggressiveness may also differ in people using a medication called metformin for their diabetes. This needs researching as melanoma is considered to be the most serious type of skin cancer because it is more likely to spread from the skin to other parts of the body than other types of skin cancer.
Predictive biomarkers of response to adalimumab treatment in patients with hidradenitis suppurativa
doi : 10.1111/bjd.20670
Volume 185, Issue 4 p. e160-e160
Hidradenitis suppurativa (HS), also known as acne inversa, is a long-lasting, inflammatory skin disease resulting in painful lesions in and around the sweat glands. It is a common disease but the average delay in accurate diagnosis is 7 years from first signs of disease.
The Cardiff Acne Disability Index
doi : 10.1111/bjd.20671
Volume 185, Issue 4 p. e161-e161
The Cardiff Acne Disability Index (CADI) is a questionnaire that measures the impact of acne on teenagers and young adults. It is used by doctors and researchers around the world.
Guidelines on how to manage rosacea
doi : 10.1111/bjd.20672
Volume 185, Issue 4 p. e162-e162
Rosacea is a common skin condition that mostly affects the central face (nose, forehead, cheeks and chin). Although rosacea mainly affects young to middle-aged adults, it can occur at any time of life. How individuals are affected can vary; patients may experience any combination of symptoms including flushing, changes to skin colour, prominent surface blood vessels, soreness, dryness, inflamed skin bumps (which may contain pus), sore eyes or facial swellings known as ‘phymas’.
Are skin conditions associated with kidney disease?
doi : 10.1111/bjd.20673
Volume 185, Issue 4 p. e163-e163
Chronic kidney disease (CKD) affects up to 13% of the population and may progress to kidney failure and death. Some risk factors for CKD are well known such as high blood pressure and diabetes. There is some evidence that inflammatory skin diseases such as eczema and psoriasis may also increase the risk of CKD.
The cardiovascular safety of the drug alitretinoin
doi : 10.1111/bjd.20674
Volume 185, Issue 4 p. e164-e164
Hand eczema is a skin disease causing intense itching and dry skin on the hands. It affects around 15% of people worldwide during their lifetime, and is more frequent among young adults. Most people can control hand eczema with treatments applied directly to the skin. Some people, however, have severe disease that can be better managed with an oral drug called alitretinoin.
Availability of guidelines to ensure appropriate care for common skin conditions
doi : 10.1111/bjd.20675
Volume 185, Issue 4 p. e165-e165
Skin-related diseases are leading causes of disability and disease burden globally. Clinical practice guidelines (CPGs), are documents that are developed with the aim of standardizing and improving treatment for patients based on the available evidence.
Oral rilzabrutinib as a treatment for patients with pemphigus vulgaris
doi : 10.1111/bjd.20676
Volume 185, Issue 4 p. e166-e166
Pemphigus is a rare and potentially life-threatening autoimmune disease with painful blistering and erosions in the skin and/or mucous membranes that line, for example, the mouth, nose and throat. Our immune system makes antibodies to fight infection and normally these antibodies do not attack our own body. However, in an autoimmune disease, such as pemphigus vulgaris, the immune system makes antibodies directed to its own components of the body (autoantibodies) that work against tissues.
A study of different types of IL-17 proteins in psoriasis
doi : 10.1111/bjd.20686
Volume 185, Issue 4 p. e167-e168
????????
doi : 10.1111/bjd.20677
Volume 185, Issue 4 p. e169-e169
??????????????, ?????????????????????????, ?????? 1% ??????????????????????, ?????????????????????????, ???????????
??????????
doi : 10.1111/bjd.20678
Volume 185, Issue 4 p. e170-e170
??????, ??????, 2 ???????????????????????????????????????????, ??????????????????, ???????????????????, ?????????????????????????????
?????????????????????????????
doi : 10.1111/bjd.20679
Volume 185, Issue 4 p. e171-e171
?????? (HS) ????????, ????????????, ???????????????????????????, ?????????????????? 7 ??
?????????
doi : 10.1111/bjd.20680
Volume 185, Issue 4 p. e172-e172
????????? (CADI) ????????????????????????????????????????
???????
doi : 10.1111/bjd.20681
Volume 185, Issue 4 p. e173-e173
??????????, ??????? (???????????) ?????????????????, ??????????????????????????; ?????????????, ??????????????????????????????? (??????) ?????????? (??“??”) ?
????????????
doi : 10.1111/bjd.20682
Volume 185, Issue 4 p. e174-e174
???? (CKD) ???? 13% ???, ???????????????????????????????, ???????????????, ???????????????????????????
??? A ??????????
doi : 10.1111/bjd.20683
Volume 185, Issue 4 p. e175-e175
???????????, ??????????????????? 15% ??????????, ??????????????????????????????????????, ??????????, ????????????? A ????????????
???????????????????
doi : 10.1111/bjd.20684
Volume 185, Issue 4 p. e176-e176
???????????????????????????? (CPG) ????????, ???????????????????
?? rilzabrutinib ??????????
doi : 10.1111/bjd.20685
Volume 185, Issue 4 p. e177-e177
???????????????????????, ????/??? (?????????????) ?????????????????????????????, ????????????????????, ?????????, ????????, ????????????????? (????) , ???????????
???????????? IL-17 ?????
doi : 10.1111/bjd.20687
Volume 185, Issue 4 p. e178-e178
?????? 1.25 ???????, ????????, ???????????, ?????????????????????????????? (IL)-17 ??????????????????????IL-17 ?????????, ???????????????????
